FI781614A - THERAPEUTIC AEMNEN - Google Patents

THERAPEUTIC AEMNEN

Info

Publication number
FI781614A
FI781614A FI781614A FI781614A FI781614A FI 781614 A FI781614 A FI 781614A FI 781614 A FI781614 A FI 781614A FI 781614 A FI781614 A FI 781614A FI 781614 A FI781614 A FI 781614A
Authority
FI
Finland
Prior art keywords
aemnen
therapeutic
therapeutic aemnen
Prior art date
Application number
FI781614A
Other languages
Finnish (fi)
Other versions
FI64594C (en
FI64594B (en
Inventor
Peter Frederick Juby
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FI781614A publication Critical patent/FI781614A/en
Application granted granted Critical
Publication of FI64594B publication Critical patent/FI64594B/en
Publication of FI64594C publication Critical patent/FI64594C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
FI781614A 1977-05-25 1978-05-22 PROTECTION OF ANTI-ALLERGIC FRAMSTRATION 3- (1H-TETRAZOL-5-YL) -4-PYRIDO (1,2-A) PYRIMIDIN-4-ONDERIVAT FI64594C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80026477 1977-05-25
US05/800,264 US4122274A (en) 1977-05-25 1977-05-25 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones

Publications (3)

Publication Number Publication Date
FI781614A true FI781614A (en) 1978-11-26
FI64594B FI64594B (en) 1983-08-31
FI64594C FI64594C (en) 1983-12-12

Family

ID=25177928

Family Applications (1)

Application Number Title Priority Date Filing Date
FI781614A FI64594C (en) 1977-05-25 1978-05-22 PROTECTION OF ANTI-ALLERGIC FRAMSTRATION 3- (1H-TETRAZOL-5-YL) -4-PYRIDO (1,2-A) PYRIMIDIN-4-ONDERIVAT

Country Status (26)

Country Link
US (1) US4122274A (en)
JP (1) JPS6050197B2 (en)
AT (1) AT365187B (en)
AU (1) AU521211B2 (en)
BE (1) BE867295A (en)
CA (1) CA1098520A (en)
CH (1) CH642656A5 (en)
CY (1) CY1218A (en)
DE (1) DE2822544A1 (en)
DK (1) DK160279C (en)
FI (1) FI64594C (en)
FR (1) FR2401159A1 (en)
GB (1) GB1596476A (en)
GR (1) GR71887B (en)
HK (1) HK25884A (en)
IE (1) IE46849B1 (en)
IT (1) IT1105040B (en)
KE (1) KE3357A (en)
LU (1) LU79694A1 (en)
MY (1) MY8500305A (en)
NL (1) NL190702C (en)
NO (1) NO150361C (en)
SE (1) SE437830B (en)
SG (1) SG73383G (en)
YU (2) YU42163B (en)
ZA (1) ZA782816B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495189A (en) * 1975-11-27 1985-01-22 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Condensed pyrimidines
HU173438B (en) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 4-oxo-1,6,7,8-tetrahydro-4h-pyrido-/1,2-a/pyrimidine derivatives with antiinflammatory and anticoagulant activity
HU180439B (en) * 1977-12-29 1983-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 9-amino-pyrido-square bracket-1,2-a-square bracket closed-pyrimidine derivatives
US4192944A (en) * 1978-04-03 1980-03-11 Bristol-Myers Company Optionally substituted 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-N-(1H-tetrazol-4-yl)carboxamides and their use as antiallergy agents
US4223031A (en) * 1978-05-05 1980-09-16 Mead Johnson & Company Azolopyrimidinones
US4491587A (en) * 1978-05-05 1985-01-01 Mead Johnson & Company Tetrazole derivatives
US4282360A (en) * 1979-10-12 1981-08-04 Hoffmann-La Roche Inc. 7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
US4419357A (en) * 1982-01-18 1983-12-06 The Dow Chemical Company 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
US4474953A (en) * 1982-09-09 1984-10-02 Riker Laboratories, Inc. Process and intermediates for the preparation of 3(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones
US4507477A (en) * 1982-09-09 1985-03-26 Riker Laboratories, Inc. Process for tetrazolyl-pyrimidinone derivatives
US4457932A (en) * 1983-07-22 1984-07-03 Bristol-Myers Company Anti-ulcer agents
DK169580B1 (en) * 1985-09-25 1994-12-12 Shionogi & Co 9- (substituted thio) -4H-pyrido [1,2-a] pyrimidin-4-one derivatives, process for their preparation, and pharmaceutical preparations containing such derivatives
JPS63183581A (en) * 1985-10-03 1988-07-28 Tokyo Tanabe Co Ltd Pyrido(1,2-a)pyrimidine derivative, production thereof and remedy for allergosis containing said derivative as active ingredient
JPS62242682A (en) * 1986-04-16 1987-10-23 Tokyo Tanabe Co Ltd Novel pyrido(1,2-a)pyrimidine derivative
JP2504788B2 (en) * 1987-11-10 1996-06-05 東京田辺製薬株式会社 Aqueous formulation of 9-methyl-3- (1H-tetrazol-5-yl) -4H-pyrido [1,2-a] pyrimidin-4-one potassium salt
US5034230A (en) * 1987-12-25 1991-07-23 Santen Pharmaceutical Co., Ltd. Anti-allergic ophthalmics
CA2010336C (en) * 1989-02-27 1996-11-19 Atsunori Sano Process for producing pyrido[1,2-a]pyrimidine derivative
HU209793B (en) * 1990-09-25 1994-11-28 Chinoin Gyogyszer Es Vegyeszet Process for the production of pyrido[1,2-a]pyrimidine-derivatives and pharmaceutical compositions containing the same
AU674016B2 (en) 1992-07-30 1996-12-05 Mitsubishi-Tokyo Pharmaceuticals, Inc. Remedy for inflammatory intestinal diseases
US5527802A (en) * 1992-10-01 1996-06-18 Bristol-Myers Squibb Company New uses of 3-tetrazolo -5,6,7,8- substituted-pyrido (1,2-a) pyrimidin-4-ones
JPH0892093A (en) * 1994-11-10 1996-04-09 Tokyo Tanabe Co Ltd Water-based pharmaceutical preparation of 9-methyl-3-(1 h-tetrazol-5-yl)-4h-pyrido (1,2-a)pyrimidin-4-one
JP4171303B2 (en) * 2001-02-26 2008-10-22 田辺三菱製薬株式会社 Preventive and / or therapeutic agent for kidney disease / renal failure
ITMI20011764A1 (en) * 2001-08-10 2003-02-10 Dinamite Dipharma Spa HIGH PURITY PEMIROLAST METHOD
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
MX2009006507A (en) * 2006-12-18 2009-08-18 Cardoz Ab New combination for use in the treatment of inflammatory disorders.
ATE543501T1 (en) * 2006-12-20 2012-02-15 Cardoz Ab COMBINATION OF PEMIROLAST AND RAMATROBAN FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
US20100184783A1 (en) * 2007-07-11 2010-07-22 Johan Raud Combination for use in the treatment of inflammatory atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
EP2303251B1 (en) * 2008-04-07 2012-05-16 Cardoz AB New combination for use in the treatment of inflammatory disorders
US20120157415A1 (en) * 2009-06-16 2012-06-21 Cardoz Ab New Crystalline Form of Pemirolast
USD661900S1 (en) 2010-02-22 2012-06-19 Bajer Design & Marketing, Inc. Collapsible structure
PE20142364A1 (en) * 2012-02-10 2015-01-10 Hoffmann La Roche COMPOUNDS TO TREAT SPINAL MUSCULAR ATROPHY
KR102099997B1 (en) 2012-03-01 2020-04-13 피티씨 테라퓨틱스, 인크. Compounds for treating spinal muscular atrophy
EA028382B1 (en) 2012-03-23 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Compounds for treating spinal muscular atrophy
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2016063085A1 (en) 2014-10-23 2016-04-28 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
EP3298017B1 (en) * 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
IL281633B (en) 2015-12-10 2022-07-01 Ptc Therapeutics Inc Methods for treating huntington's disease
GB201601138D0 (en) * 2016-01-21 2016-03-09 Rspr Pharma Ab New use
EP3544435A4 (en) 2016-11-28 2020-11-04 PTC Therapeutics, Inc. Methods for modulating rna splicing
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (en) 2017-06-14 2020-07-03 Ptc医疗公司 Methods of modifying RNA splicing
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CA3094703A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072485A (en) * 1960-08-24 1963-01-08 Eastman Kodak Co Optically sensitized azido polymers for photomechanical resist compositions
AT286990B (en) * 1966-11-02 1971-01-11 Chinoin Gyogyszer Es Vegyeszet Process for the preparation of new homopyrimidazole derivatives and their salts
US3960847A (en) * 1972-04-17 1976-06-01 E. R. Squibb & Sons, Inc. 9-Substituted-4-oxopyrido(1,2-α)pyrimidine-3-carboxylic acids and derivatives thereof
US3929787A (en) * 1974-04-22 1975-12-30 Squibb & Sons Inc 6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones
US3960863A (en) * 1974-06-25 1976-06-01 Sankyo Company Limited Pyrido[1,2-a]pyrimidinone derivatives
US4017625A (en) * 1975-08-01 1977-04-12 Pfizer Inc. Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor
US4012387A (en) * 1975-09-18 1977-03-15 Warner-Lambert Company Benzo-[g]pyrido[2,1-b]quinazolinones

Also Published As

Publication number Publication date
BE867295A (en) 1978-11-20
IT7849523A0 (en) 1978-05-24
FR2401159B1 (en) 1983-05-20
YU123678A (en) 1983-02-28
SG73383G (en) 1984-08-03
YU42163B (en) 1988-06-30
FI64594C (en) 1983-12-12
DK160279B (en) 1991-02-18
HK25884A (en) 1984-03-30
DK160279C (en) 1991-07-22
IT1105040B (en) 1985-10-28
NO150361C (en) 1984-10-03
ZA782816B (en) 1979-05-30
KE3357A (en) 1984-02-03
DE2822544A1 (en) 1978-12-07
FI64594B (en) 1983-08-31
MY8500305A (en) 1985-12-31
DK228878A (en) 1978-11-26
NL7805534A (en) 1978-11-28
NL190702B (en) 1994-02-01
AT365187B (en) 1981-12-28
FR2401159A1 (en) 1979-03-23
IE781036L (en) 1978-11-25
SE7805954L (en) 1978-11-26
IE46849B1 (en) 1983-10-05
NL190702C (en) 1994-07-01
JPS5436294A (en) 1979-03-16
JPS6050197B2 (en) 1985-11-07
CY1218A (en) 1984-04-06
YU233082A (en) 1988-08-31
NO150361B (en) 1984-06-25
GR71887B (en) 1983-08-04
US4122274A (en) 1978-10-24
AU3631978A (en) 1979-11-29
NO781786L (en) 1978-11-28
GB1596476A (en) 1981-08-26
YU44212B (en) 1990-04-30
SE437830B (en) 1985-03-18
CH642656A5 (en) 1984-04-30
DE2822544C2 (en) 1988-10-27
ATA373278A (en) 1981-05-15
CA1098520A (en) 1981-03-31
LU79694A1 (en) 1979-02-02
AU521211B2 (en) 1982-03-25

Similar Documents

Publication Publication Date Title
FI781613A (en) THERAPEUTIC HYDANTOINFOERENINGAR
FI781614A (en) THERAPEUTIC AEMNEN
ATA784877A (en) HOERGERAET
BE857403A (en) REACTOR-EXCHANGER
DK156364C (en) RADIATION-HEAT UNIT
IS2443A7 (en) therapeutic agents
FI781666A (en) AVFORMNINGSMATERIAL FOER DENTALT BRUK
AT376049B (en) TARGETERS
AR221072A1 (en) BENCH-STAIRCASE
FI781768A (en) YTBEHANDLAT MINERALFYLLMEDEL
DK148408C (en) MEDICAL CLAIMS
AT367290B (en) MENSTRUALTAMPON
BE855216A (en) GRONDBEWERKINGSMACHINE
SE7807416L (en) THERAPEUTIC SOCK
FI783326A (en) THERAPEUTIC AEMNEN
BE5T2 (en) WASMIDDELRN
AT361804B (en) HAIRCUTTER
DK370578A (en) RITTEBOM UNIT
SE7806367L (en) KABELMUFF
FI780184A (en) NOW VACCIN
FI782849A (en) THERAPEUTIC MEDEL
AT359804B (en) ABWÄZFRAESER
DD133342A5 (en) VIGNOLSCHIENENWEICHE
BE853850A (en) AABEETDETEKTOR
SE7805175L (en) RAMASSA

Legal Events

Date Code Title Description
MA Patent expired
MA Patent expired

Owner name: BRISTOL-MYERS CO